Abstract
Pancreatic tumors exhibit high morbidity rates and a grim prognosis. In recent years, significant progress in translational research and technological advancements in scanning equipment have facilitated the rapid adoption of molecular radionuclide imaging for pancreatic tumors into standard clinical practice. One of the most widely utilized techniques is metabolic imaging with F-18 fluorodeoxyglucose positron emission tomography (PET), which is invaluable in the staging process, assessing treatment responses, and monitoring follow-ups for pancreatic ductal adenocarcinoma. Moreover, the introduction of integrated PET/magnetic resonance imaging systems has the potential to further broaden the applications of these imaging techniques, opening doors to innovative clinical uses. Despite these advancements, there remains a crucial need for continued research to optimize the application of advanced molecular imaging techniques and develop novel radiotracers. Such research is essential to achieving better clinical outcomes for patients diagnosed with pancreatic tumors, ultimately leading to more effective and personalized treatment strategies.
Keywords:
Pancreas cancer, molecular imaging, PET/CT
References
1
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
2
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039-1049.
3
Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
4
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379:2395-2406.
5
Perri G, Prakash L, Qiao W, et al. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020;155:832-839.
6
Sigel K, Zhou M, Park YA, et al. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Semin Oncol. 2021;48:69-75.
7
Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
8
Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:77-87.
9
Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553-565.
10
Mayerle J. Pancreatic cancer: why the cell of origin matters. Nat Rev Gastroenterol Hepatol. 2022;19:279.
11
Bhattacharya A, Santhoshkumar A, Kurahara H, Harihar S. Metastasis Suppressor Genes in Pancreatic Cancer: An Update. Pancreas. 2021;50:923-932.
12
Halbrook CJ, Lyssiotis CA. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Cancer Cell. 2017;31:5-19.
13
Strobel K, Heinrich S, Bhure U, et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med. 2008;49:1408-1413.
14
Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma. Abdom Radiol (NY). 2018;43:415-434.
15
Daamen LA, Groot VP, Goense L, et al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Eur J Radiol. 2018;106:128-136.
16
Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol. 2012;199:952-967.
17
Kumar R, Sharma A, Garg P, Sharma R, Datta-Gupta S. Role of dual-point 18F-FDG-PET/CT in the diagnosis of pancreatic adenocarcinoma, in patients with and without concomitant chronic pancreatitis: Comparison with CECT and EUS. Pancreatology. 2021;21:746-754.
18
Kato K, Nihashi T, Ikeda M, et al. Limited efficacy of (18)F-FDG PET/CT for differentiation between metastasis-free pancreatic cancer and mass-forming pancreatitis. Clin Nucl Med. 2013;38:417-421.
19
Nagamachi S, Nishii R, Wakamatsu H, et al. The usefulness of (18)F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with (18)F-FDG PET/CT. Ann Nucl Med. 2013;27:554-563.
20
Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology. 2010;257:87-96.
21
Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144-151.
22
Tang S, Huang G, Liu J, et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol. 2011;78:142-150.
23
Krishna NB, Mehra M, Reddy AV, Agarwal B. EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. Gastrointest Endosc. 2009;70:70-79.
24
Zhang Y, Frampton AE, Martin JL, et al. 18F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. Nucl Med Biol. 2012;39:982-985.
25
Lee SW, Shim SR, Jeong SY, Kim SJ. Comparison of Preoperative Imaging Modalities for the Assessment of Malignant Potential of Pancreatic Cystic Lesions: A Network Meta-analysis. Clin Nucl Med. 2022;47:849-855.
26
Expert Panel on Gastrointestinal I, Qayyum A, Tamm EP, et al. ACR Appropriateness Criteria((R)) Staging of Pancreatic Ductal Adenocarcinoma. J Am Coll Radiol. 2017;14:S560-S569.
27
Ghaneh P, Hanson R, Titman A, et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technol Assess. 2018;22:1-114.
28
Ford EC, Herman J, Yorke E, Wahl RL. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med. 2009;50:1655-1665.
29
Li XX, Liu NB, Zhu L, et al. Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer. Br J Radiol. 2015;88:20140590.
30
Kishi T, Matsuo Y, Nakamura A, et al. Comparative evaluation of respiratory-gated and ungated FDG-PET for target volume definition in radiotherapy treatment planning for pancreatic cancer. Radiother Oncol. 2016;120:217-221.
31
Chang JS, Choi SH, Lee Y, et al. Clinical usefulness of (1)(8)F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2014;90:126-133.
32
Bjerregaard JK, Fischer BM, Vilstrup MH, et al. Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer. Acta Oncol. 2011;50:1250-1252.
33
Cameron K, Golan S, Simpson W, et al. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging. 2011;36:463-471.
34
Yamamoto T, Sugiura T, Mizuno T, et al. Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:677-684.
35
Choi HJ, Kang CM, Jo K, et al. Prognostic significance of standardized uptake value on preoperative (1)(8)F-FDG PET/CT in patients with ampullary adenocarcinoma. Eur J Nucl Med Mol Imaging. 2015;42:841-847.
36
Pimiento JM, Davis-Yadley AH, Kim RD, et al. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer. Clin Nucl Med. 2016;41:177-181.
37
Ahn SJ, Park MS, Lee JD, Kang WJ. Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer. Ann Nucl Med. 2014;28:430-435.
38
Chen BB, Tien YW, Chang MC, et al. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2018;45:1205-1217.
39
Chang J, Schomer D, Dragovich T. Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications. Biomed Res Int. 2015;2015:269641.
40
Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA. State-of-the-art PET/CT of the pancreas: current role and emerging indications. Radiographics 2012;32:1133-1158; discussion 1158-1160.
41
Klaassen R, Bennink RJ, van Tienhoven G, et al. Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer. Radiother Oncol. 2015;116:94-99.
42
Chalkidou A, Landau DB, Odell EW, Cornelius VR, O’Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer. 2012;48:3499-3513.
43
Quigley NG, Czech N, Sendt W, Notni J. PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin” alphavbeta6. Eur J Nucl Med Mol Imaging. 2021;48:4107-4108.
44
Quigley NG, Steiger K, Hoberuck S, et al. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the “Cancer Integrin” alphavbeta6 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging. 2022;49:1136-1147.
45
Feng X, Wang Y, Lu D, et al. Clinical Translation of a (68)Ga-Labeled Integrin alpha(v)beta(6)-Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer. J Nucl Med. 2020;61:1461-1467.
46
Deng M, Chen Y, Cai L. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Imaging of Pancreatic Cancer With Liver Metastases. Clin Nucl Med. 2021;46:589-591.
47
Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:2877-2888.
48
Rohrich M, Naumann P, Giesel FL, et al. Impact of (68)Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. J Nucl Med. 2021;62:779-786.
49
Zhu Z, Cheng K, Yun Z, et al. [(18)F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2023;50:3425-3438.
50
Novruzov E, Giesel FL, Mori Y, et al. Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [(18)F]FAPI-74 with [(18)F]FDG in Patients with PDAC: A Prospective Exploratory Study. Cancers (Basel). 2023;15.
51
Kaghazchi F, Divband G, Amini H, Adinehpour Z, Akbarian Aghdam R. 68 Ga-FAPI-46 and 18 F-FDG in Advanced Metastatic Pancreatic Cancer. Clin Nucl Med. 2022;47:e666-e669.
52
Elsherif SB, Virarkar M, Javadi S, Ibarra-Rovira JJ, Tamm EP, Bhosale PR. Pancreatitis and PDAC: association and differentiation. Abdom Radiol (NY). 2020;45:1324-1337.
53
Birgin E, Hablawetz P, Teoule P, Ruckert F, Wilhelm TJ. Chronic pancreatitis and resectable synchronous pancreatic carcinoma: A survival analysis. Pancreatology. 2018;18:394-398.
54
Kirkegard J, Mortensen FV, Cronin-Fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2017;112:1366-1372.
55
Schima W, Bohm G, Rosch CS, Klaus A, Fugger R, Kopf H. Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma: CT and MR imaging for differentiation. Cancer Imaging. 2020;20:52.
56
Ruan Z, Jiao J, Min D, et al. Multi-modality imaging features distinguish pancreatic carcinoma from mass-forming chronic pancreatitis of the pancreatic head. Oncol Lett. 2018;15:9735-9744.
57
Iglesias-Garcia J, Lindkvist B, Larino-Noia J, Dominguez-Munoz JE. The role of EUS in relation to other imaging modalities in the differential diagnosis between mass forming chronic pancreatitis, autoimmune pancreatitis and ductal pancreatic adenocarcinoma. Rev Esp Enferm Dig. 2012;104:315-321.
58
Dutta AK, Chacko A. Head mass in chronic pancreatitis: Inflammatory or malignant. World J Gastrointest Endosc. 2015;7:258-264.
